Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.
The Annals of Thoracic Surgery|April 23, 2016
Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancerYolanda I Garces, Scott H Okuno, Steven E Schild, et al.
Cancer|July 19, 2006
A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trialsSumithra J Mandrekar, Steven E Schild, Shauna L Hillman, et al.
JCO Oncology Practice|June 14, 2021
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent FormsYahya Almodallal, Quyen Duong, Daniel Satele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426Alex A Adjei, Sumithra J Mandrekar, Grace K Dy, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
The Annals of Thoracic Surgery|April 23, 2016
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung CancerRamaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Cancer Chemotherapy and Pharmacology|June 10, 2006
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignanciesCynthia Ma, Sumithra J Mandrekar, Steven R Alberts, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.
The Annals of Thoracic Surgery|April 23, 2016
Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancerYolanda I Garces, Scott H Okuno, Steven E Schild, et al.
Cancer|July 19, 2006
A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trialsSumithra J Mandrekar, Steven E Schild, Shauna L Hillman, et al.
JCO Oncology Practice|June 14, 2021
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent FormsYahya Almodallal, Quyen Duong, Daniel Satele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426Alex A Adjei, Sumithra J Mandrekar, Grace K Dy, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
The Annals of Thoracic Surgery|April 23, 2016
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung CancerRamaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Cancer Chemotherapy and Pharmacology|June 10, 2006
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignanciesCynthia Ma, Sumithra J Mandrekar, Steven R Alberts, et al.
Pageof 16